期刊
DRUG DESIGN DEVELOPMENT AND THERAPY
卷 9, 期 -, 页码 4989-4995出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/DDDT.S90670
关键词
folate receptor alpha; lung cancer; immunotherapy
资金
- Shandong Cancer Hospital and Institute [09-37]
- Shandong Provincial Natural Science Foundation [ZR2015YL031]
Lung cancer remains the leading common cause of cancer-related death, with non-small-cell lung cancer (NSCLC) accounting for 80% of all cases. To date, platinum-based doublet chemotherapy is the cornerstone of first-line therapy. However, these agents have limited use in patients who have relapsed and have metastatic disease. Therefore, novel strategies are required to improve the clinical outcome. Folate receptor alpha (FRA) is overexpressed in the majority of NSCLC, particularly in lung adenocarcinomas. FRA is largely absent from normal tissue, making it an attractive therapeutic target. In this review, we discuss FRA expression in NSCLC, conjugated FRA agents, monoclonal antibody, and FRA-specific T-cell-based therapeutic strategies aiming to improve the cure rate of FRA-expressing NSCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据